Neumora Therapeutics, Inc. (NMRA) - 10-K Summary
Business Context and Reporting Period
Company: Neumora Therapeutics, Inc.
Filing Type: Annual Report on Form 10-K
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Neumora is a clinical-stage biopharmaceutical company focused on developing novel therapies for brain and centrally mediated diseases using a "precision neuroscience" approach. The company has no approved products and has not generated any product revenue.
Key Pipeline Assets:
- Navacaprant (NMRA-140): Phase 3 program for Major Depressive Disorder (MDD). The initial KOASTAL-1 study (announced Jan 2025) did not meet primary endpoints. KOASTAL-2 and -3 are fully enrolled with topline data expected in Q2 2026.
- NMRA-511: Phase 1b results (Q1 2026) showed clinically meaningful effects for agitation in Alzheimer's disease. Phase 2 initiation planned for Q1 2027.
- NMRA-898: Lead M4 PAM for schizophrenia. Phase 1 MAD data expected in H2 2026.
- NMRA-215: NLRP3 inhibitor for obesity. Preclinical data showed significant weight loss. Clinical entry delayed to Q1 2027 due to unexpected findings in a rat toxicology study requiring a for-cause audit and repeat study.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(236.9) million | $(243.8) million |
| Operating Expenses | $(241.2) million | $(263.5) million |
| Cash and Cash Equivalents (Dec 31, 2025) | $182.5 million | $142.1 million |
| Accumulated Deficit | $(1,184.1) million | $(947.2) million |
| Long-Term Debt (Net) | $54.5 million | $0 |
Debt Details: In May 2025, the company entered a loan agreement with K2 HealthVentures LLC for up to $125.0 million. As of Dec 31, 2025, $60.0 million was drawn. The debt bears a variable interest rate (minimum 10.45%) and includes conversion options for the lender.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $6.9 million (2.8%) primarily due to a $24.9 million decrease in Research and Development (R&D) expenses and a $2.4 million decrease in General and Administrative (G&A) expenses.
- R&D Expense Drivers: The decrease in R&D was driven by a $12.2 million reduction in navacaprant program costs following the completion of the KOASTAL-1 trial, and lower personnel costs due to reduced stock-based compensation (excluding a one-time $3.6 million modification expense in 2024) and headcount reductions.
- Interest Income Decline: Interest income dropped by $11.6 million to $8.3 million due to lower balances in cash equivalents and marketable securities.
- Debt Incurrence: The company incurred $3.2 million in interest expense in 2025 related to the new term loan, compared to zero in 2024.
- Acquired IPR&D: Recognized $5.0 million in acquired in-process research and development expenses in 2025 related to a Vanderbilt milestone, compared to none in 2024.
Guidance, Outlook, and Risks
Outlook and Milestones:
- 2026 Data Readouts: Expect topline data for navacaprant (KOASTAL-2 and -3) in Q2 2026; NMRA-511 MAD extension data and NMRA-898 MAD data in H2 2026.
- Liquidity: Management believes existing cash ($182.5 million) will fund operations for at least the next 12 months. Additional financing will be required to complete development and commercialization.
- Capital Raising: The company maintains an At-The-Market (ATM) program with Leerink Partners (up to $300 million gross proceeds). Net proceeds of $19.7 million were raised via ATM in 2025.
Key Risks and Contingencies:
- Clinical Failure Risk: The failure of the initial Phase 3 navacaprant study (KOASTAL-1) highlights the high risk of clinical development in neuropsychiatric disorders. Future success depends on the optimized KOASTAL-2 and -3 studies.
- Regulatory and Toxicology Delays: NMRA-215 clinical entry is delayed to 2027 due to unexpected adverse findings in a rat toxicology study, currently under audit.
- Contingent Consideration: Significant future cash or equity obligations exist under license agreements with BlackThorn (up to $915 million total milestones), Amgen (up to $720 million), and Vanderbilt (up to $422 million).
- Legal Proceedings: A putative securities class action lawsuit was filed in February 2025 regarding the IPO and navacaprant prospects. The company has moved to dismiss.
- Stock Price Volatility: The company previously faced Nasdaq delisting risks due to the $1.00 minimum bid price requirement but regained compliance in July 2025.
Investor Verification Checklist
- Navacaprant Phase 3 Data: Verify the topline results of KOASTAL-2 and -3 expected in Q2 2026, as the initial Phase 3 study failed to meet primary endpoints.
- NMRA-215 Toxicology Resolution: Confirm the outcome of the for-cause audit and the repeat 13-week rat toxicology study to assess the timeline for clinical entry.
- Debt Covenants: Review the specific liquidity covenants and milestone triggers in the K2 HealthVentures loan agreement to ensure compliance and avoid default.
- Cash Burn Rate: Monitor quarterly cash burn to validate the "12-month runway" assertion given the high cost of Phase 3 trials and potential need for additional equity financing.
- Contingent Milestone Triggers: Track progress on development milestones for BlackThorn, Amgen, and Vanderbilt assets to assess potential future dilution or cash outflows.